Colon-Release Cholestyramine Pellets for Bile Acid Malabsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bile acid malabsorption, particularly using cholestyramine, are associated with significant side effects such as constipation, interactions with other drugs, and malabsorption of fats and fat-soluble vitamins, and require high doses and frequent administration, which can lead to patient non-compliance due to poor taste and texture.
Innovation Solution
Development of an oral formulation comprising small, stable cholestyramine pellets coated with a colon-release coating that delays the release of cholestyramine until it reaches the colon, allowing for a reduced dose and minimizing interactions with other gastrointestinal components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholestyramine is administered orally to treat bile acid malabsorption, then excess bile acids are bound in the gastrointestinal tract, but significant side effects occur including constipation, drug interactions, and malabsorption of fats and fat-soluble vitamins
Solution Approach 1:
The invention segments the gastrointestinal tract into different regions (small intestine vs. colon) and targets cholestyramine release specifically to the colon using pH-dependent coating technology. This spatial segmentation allows the drug to bind bile acids where they cause harm (colon) while avoiding areas where side effects occur (small intestine), thereby resolving the contradiction between effectiveness and harmful effects
Solution Approach 2:
The pH-dependent coating acts as an intermediary barrier that controls the release of cholestyramine. This coating remains intact in the acidic environment of the stomach and neutral pH of the small intestine, preventing premature release and associated side effects. The coating dissolves only in the colon where bile acid malabsorption occurs, enabling targeted delivery that reduces harmful effects while maintaining therapeutic effectiveness
2Reliability
If high doses of cholestyramine are administered to ensure adequate bile acid binding, then therapeutic effect is improved, but patient compliance deteriorates due to poor taste, texture, and frequent administration requirements
Solution Approach 1:
By segmenting the release location to the colon, the invention enables lower doses of cholestyramine to achieve the same therapeutic effect, as the drug is concentrated where it is most needed. This reduces the total burden of medication and improves patient compliance while maintaining therapeutic effectiveness
Solution Approach 2:
The invention changes the release parameter of cholestyramine from immediate release in the upper GI tract to delayed release in the colon through pH-dependent coating. This parameter change allows for reduced dosing frequency and improved patient compliance while maintaining or enhancing therapeutic effect through targeted delivery
3Reliability
If cholestyramine is released in the small intestine, then bile acid binding occurs early, but interactions with other drugs and nutrients increase leading to malabsorption
Solution Approach 1:
The invention segments the site of action to the colon, separating bile acid binding from the small intestine where drug and nutrient absorption occurs. This spatial separation eliminates interactions between cholestyramine and other substances while maintaining effective bile acid binding in the colon where bile acid malabsorption causes symptoms
Solution Approach 2:
The pH-dependent coating serves as an intermediary that prevents cholestyramine from interacting with drugs and nutrients in the small intestine. The coating remains intact throughout the small intestine, blocking any potential interactions, and only dissolves in the colon where bile acid binding is needed, thus eliminating harmful interactions while maintaining therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves greater than 70% release of cholestyramine in the colon, reducing side effects and improving patient compliance by minimizing interactions with other drugs and nutrients, while effectively binding excess bile acids to alleviate diarrhea.
Implementation Method 1
comprising a plurality of cholestyramine pellets that are coated with a colon release coating
Implementation Method 2
Cholestyramine (or colestyramine; CAS Number 11041-12-6) is a strongly basic anion-exchange resin that is practically insoluble in water and is not absorbed from the gastrointestinal tract. Instead, it absorbs and combines with the bile acids in the intestine to form an insoluble complex
Data Source
AI summary
The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.